Item Number: CLINDASEP
Clindaseptin Capsules are indicated for the treatment of infected wounds, abscesses, superficial pyoderma and oral cavity/dental infections caused by or associated with clindamycin-sensitive staphylococci, streptococci, bacteroidaceae, Fusobacterium necrophorum, Clostridium perfringens and osteomyelitis caused by Staphylococcus aureus. Clindaseptin Capsules can also be used to help provide antimicrobial cover during dental procedures.
Dosage and administration
For oral administration.
For treatment of infected wounds, abscesses, oral cavity/dental infections, administer 5.5 mg/kg bodyweight every 12 hours for 7 - 10 days.
Treatment may be extended to a maximum of 28 days based on clinical judgement. If no improvement is seen within 4 days, the sensitivity of the pathogens involved should be redetermined.
For the treatment of superficial pyoderma administer 11 mg/kg every 24 hours. Continue treatment for at least 21 days.
For the treatment of osteomyelitis administer 11mg/kg every 12 hours for at least 28 days. If no improvement is seen within 14 days, the sensitivity of the pathogens involved should be redetermined.
To help provide antimicrobial cover during dental procedures, a 10 day course of 5.5mg/kg every 12 hours is recommended (beginning 5 days before the intended procedure and continuing for 5 days thereafter).
Contra-indications, warnings, etc
Do not administer to animals with hypersensitivity to clindamycin or lincomycin.
Do not administer to rabbits, hamsters, guinea pigs, chinchillas, horses or ruminants because ingestion of clindamycin by these species may result in severe gastro-intestinal disturbance.
Before use of Clindaseptin capsules, the identification of causative pathogenic micro-organisms should be carried out and their susceptibility to clindamycin should be established.
Clindamycin and lincomycin show parallel resistance. There is a partial cross-resistance to erythromycin and other macrolide antibiotics.
Special precautions for use in animals
During prolonged therapy of one month or greater, periodic liver and kidney function tests and blood counts should be performed. Patients with severe renal and/or hepatic disturbances accompanied by severe metabolic aberrations should be dosed with caution and should be monitored by serum examination during high dose clindamycin therapy.
Whenever possible, the veterinary medicinal product should only be used based on susceptibility testing.
Adverse reactions (frequency and seriousness)
Vomiting and diarrhoea are observed occasionally. Clindamycin sometimes causes the overgrowth of non sensitive organisms such as resistant clostridia and yeasts. In cases of superinfection, appropriate measures should be taken according to the clinical situation.
Use during pregnancy and lactation
While high dose studies in rats suggests that clindamycin is not a teratogen and does not significantly affect the breeding performance of males and females, safety during pregnancy and lactation or in breeding male dogs has not been established. Therefore, the administration of the veterinary medicinal product during pregnancy and lactation should be the subject of a benefit/risk assessment by the veterinarian.
Interaction with other medicinal products and other forms of interaction
Neuromuscular blocking effects have been observed with clindamycin possibly leading to an increase of efficacy of other neuromuscular blocking agents. The concomitant use of such drugs must be handled with care.
Clindamycin should not be used concomitantly with chloramphenicol or macrolides because they may antagonise each other at the site of action.
Those with known hypersensitivity to lincosamides (lincomycin, clindamycin) should not handle the product. If you develop symptoms following exposure, such as a skin rash, you should seek medical advice and show the Doctor this warning. Swelling of the face, lips or eyes, or breathing difficulties are more serious symptoms and require urgent medical attention. Accidental ingestion of this product may cause transient gastrointestinal effects, and so should be avoided. If a child accidentally consumes this product, seek medical advice.
Symptoms of overdose include vomiting, inappetency and diarrhoea. In such cases, treatment should be stopped immediately and the dogs treated symptomatically.
This veterinary product does not require any special storage conditions.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Legal category: POM-V
Blister strips composed of PVC/PE/PVdC film and sealed with aluminium foil. Capsules are presented as 2, 4, 6, 8 or 10 per strip.
Carton with blister strips of 100 capsules.
Not all pack sizes may be marketed.
Clindamycin is rapidly absorbed; following oral administration up to 90% of the active ingredient is absorbed from the gastro-intestinal tract.
After a single administration of one tablet to fasting dogs maximum plasma levels (Cmax) of 5 µg/ml are found compared to 3.4 µg/ml in non-fasting dogs. Bioavailability is greater in fasting dogs than fed dogs.
Clindamycin crosses the placental barrier and can be detected in milk.